Prospective Trial of the Effect of Preoperative Forced-air Warming on Perioperative Body Temperature Following Neuraxial Anesthesia in Total Hip Arthroplasty Patients
This study is enrolling participants by invitation only.
Sponsor:
University of Wisconsin, Madison
Information provided by (Responsible Party):
Kristopher Schroeder, University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT01626690
First received: June 12, 2012
Last updated: March 8, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if placement of a forced-air warming device prior to institution of regional anesthesia improves perioperative temperature control in patients undergoing total hip arthroplasty.
| Condition | Intervention | Phase |
|---|---|---|
|
Perioperative Hypothermia |
Device: Bair-Paws Warming Device Device: Bair-Hugger Warming Device |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Prospective Randomized Control Trial of the Effect of Preoperative Forced-air Warming on Perioperative Body Temperature Following Neuraxial Anesthesia in Total Hip Arthroplasty Patients |
Resource links provided by NLM:
Further study details as provided by University of Wisconsin, Madison:
Primary Outcome Measures:
- Temporal artery temperature at the time of incision. [ Time Frame: The treatment period starts with the patient consenting to the study and application of preoperative forced-air warming device and ends when the patient leaves the PACU (average 4-8 hours following enrollment). ] [ Designated as safety issue: Yes ]Temporal artery temperature readings (in degrees celsius) will be obtained at the time of incision and every 30 minutes while in the OR.
Secondary Outcome Measures:
- Temporal artery temperature before entering OR [ Time Frame: The treatment period starts with the patient consenting to the study and application of preoperative forced-air warming device and ends when the patient leaves the PACU (average 4-8 hours following enrollment). ] [ Designated as safety issue: No ]
- Temporal artery temperature every 30 minutes in operating room. [ Time Frame: The treatment period starts with the patient consenting to the study and application of preoperative forced-air warming device and ends when the patient leaves the PACU (average 4-8 hours following enrollment). ] [ Designated as safety issue: Yes ]
- Temporal artery temperature on arrival to recovery room [ Time Frame: The treatment period starts with the patient consenting to the study and application of preoperative forced-air warming device and ends when the patient leaves the PACU (average 4-8 hours following enrollment). ] [ Designated as safety issue: Yes ]
- Incidence of postoperative shivering in recovery room. [ Time Frame: The treatment period starts with the patient consenting to the study and application of preoperative forced-air warming device and ends when the patient leaves the PACU (average 4-8 hours following enrollment). ] [ Designated as safety issue: Yes ]
- Intraoperative blood loss. [ Time Frame: The treatment period starts with the patient consenting to the study and application of preoperative forced-air warming device and ends when the patient leaves the PACU (average 4-8 hours following enrollment). ] [ Designated as safety issue: Yes ]Intraoperative blood loss in mL's.
- Incidence of perioperative cardiac events. [ Time Frame: The treatment period starts with the patient consenting to the study and application of preoperative forced-air warming device and ends when the patient leaves the PACU (average 4-8 hours following enrollment). ] [ Designated as safety issue: Yes ]Incidence of perioperative arrhythmias or myocardial ischemia.
- Temporal artery verus SpotOn (3M) Temperature Readings. [ Time Frame: The treatment period starts with the patient consenting to the study and application of preoperative forced-air warming device and ends when the patient leaves the PACU (average 4-8 hours following enrollment). ] [ Designated as safety issue: No ]At each temperature measurement interval, will record temperature with both temporal artery thermometer and SpotOn temperature monitoring device (3M).
| Estimated Enrollment: | 120 |
| Study Start Date: | May 2012 |
| Estimated Primary Completion Date: | May 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Pre-Warming |
Device: Bair-Paws Warming Device
Bair-Paws device to be applied to patient and used for perioperative (including preoperative) warming.
|
| Active Comparator: Control |
Device: Bair-Hugger Warming Device
Bair-Hugger device to be applied to patient and used for intraoperative warming (current standard of care at our institution).
|
Eligibility| Ages Eligible for Study: | 55 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- patients undergoing total hip arthroplasty under neuraxial anesthesia,
- age 55-85,
- BMI 18-40
Exclusion Criteria:
- allergy to local anesthetics,
- patients electing to have general anesthesia for their total hip arthroplasty,
- pregnancy,
- prisoners,
- patients unable to give informed consent,
- English as a second language,
- active infectious or febrile illness (measured temperature > 37.5 degrees Celsius).
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Kristopher Schroeder, Assistant Professor, University of Wisconsin, Madison |
| ClinicalTrials.gov Identifier: | NCT01626690 History of Changes |
| Other Study ID Numbers: | 2011-0823 |
| Study First Received: | June 12, 2012 |
| Last Updated: | March 8, 2013 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Hypothermia Body Temperature Changes Signs and Symptoms Anesthetics Central Nervous System Depressants |
Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013